Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome

被引:57
作者
Fujinaga, S. [1 ]
Kaneko, K. [1 ]
Muto, T. [1 ]
Ohtomo, Y. [1 ]
Murakami, H. [1 ]
Yamashiro, Y. [1 ]
机构
[1] Saitama Childrens Med Ctr, Div Nephrol, Iwatsuki, Saitama 3398551, Japan
关键词
D O I
10.1136/adc.2005.080960
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Cyclosporine A ( CsA) has been widely used in children with steroid dependent and steroid resistant nephrotic syndrome ( NS) because of its efficacy in relieving these patients from systemic side effects of steroids. However, its long term use is controversial, since chronic CsA induced nephropathy ( CsAN) may develop in a considerable number of patients. Aims and Methods: In order to clarify the risk factors for the development of CsAN, the clinical characteristics of children with steroid dependent or steroid resistant NS taking CsA ( target blood trough levels 50 - 150 ng/ml) for more than six months, managed at a single centre, were retrospectively analysed. Results: Thirteen of 30 children ( 24 boys and 6 girls) taking CsA ( mean duration 43 months, range 6 - 144) had CsAN defined as the presence of CsA associated arteriopathy with or without striped tubulointerstitial lesions. The multivariate analysis revealed that CsA treatment for more than 36 months and an age younger than 5 years at the start of CsA treatment were independent risk factors for the development of CsAN. The univariate analysis also showed that patients with CsAN had more frequent relapses during CsA treatment than those without CsAN. Conclusion: An alternative treatment should be seriously considered after a 36 month administration of CsA in order to prevent CsAN. Data also suggest that CsA treatment in children younger than 5 years should be avoided if possible.
引用
收藏
页码:666 / 670
页数:5
相关论文
共 29 条
[1]  
[Anonymous], 1981, KIDNEY INT, V20, P765
[2]  
[Anonymous], 1982, J PEDIATR-US, V101, P514
[3]  
BRODEHL J, 1982, NEW ENGL J MED, V306, P451
[4]  
CAPODICASA G, 1986, INT J PED NEPHROL, V7, P69
[5]   Preprandial C2 monitoring of cyclosporine treatment in children with nephrotic syndrome [J].
Fujinaga, S ;
Kaneko, K ;
Takada, M ;
Ohtomo, Y ;
Akashi, S ;
Yamashiro, Y .
PEDIATRIC NEPHROLOGY, 2005, 20 (09) :1359-1360
[6]  
FUJINAGA S, 2004, JPN J PEDIAT, V108, P1211
[7]  
Gregory MJ, 1996, J AM SOC NEPHROL, V7, P543
[8]  
HABIB R, 1994, CLIN NEPHROL, V42, P141
[9]   Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome [J].
Hamahira, K ;
Iijima, K ;
Tanaka, R ;
Nakamura, H ;
Yoshikawa, N .
PEDIATRIC NEPHROLOGY, 2001, 16 (09) :723-727
[10]   Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine [J].
Hino, S ;
Takemura, T ;
Okada, M ;
Murakami, K ;
Yagi, K ;
Fukushima, K ;
Yoshioka, K .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (06) :932-939